ESG News For Bristol-Myers Squibb Company

Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research

“Humankind 100” ranking celebrates companies’ positive human impact

Alphabet earns the top spot for the third year in a row

The International SOS Foundation has revealed its 2024 Duty of Care Awards shortlist today.

At BMS, our vision to transform patients’ lives through science extends to all patients. That is why we have a long-standing commitment to promote health equity and help people in underserved communities access the care and medicines they need.

At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development and delivery of innovative medicines that help patients prevail over serious diseases.

BMS today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), as part of a mid-year update on its environmental initiatives, highlighting progress in reducing emissions across its operations and supply chain.

BMS has earned a top score of 100 on the 2024 Disability Equality Index®, naming BMS a Best Place to Work for Disability Inclusion in the U.S., U.K. and Brazil. BMS has earned this score for the sixth consecutive year in the U.S. and for the first time in the U.K. and Brazil.

ristol Myers Squibb (NYSE: BMY) has been named to the prestigious 2023 Dow Jones Sustainability Index (DJSI) North America, validating the company’s meaningful progress, evolved strategy and aspirational goals toward its environmental, social and governance efforts.

Globally, communities are struggling to support growing healthcare needs. This is especially true in regions with limited financial resources, collectively known as low- and middle-income countries (LMICs). Although LMIC populations have grown nearly four times faster.

The Company enters strategic collaboration with the Access to Oncology Medicines (ATOM) Coalition to expand access to immuno-oncology therapy Opdivo™ in select countries

BMS announced ASPIRE (Accessibility, Sustainability, Patient-centric, Impact, Responsibility and Equity), a 10-year strategy to advance access to our innovative treatments and help patients in low- and middle-income countries.

Since 1887, BMS has enabled positive change for patients around the world, and I am honored to continue this legacy as Board Chair and CEO. Our obligation to advance this legacy is profound.

Bristol Myers Squibb (NYSE: BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company’s meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts.

Company builds on its strengths to advance patient access, product innovation, culture and inclusion and diversity

Bristol Myers Squibb published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company’s meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts.

Bristol Myers Squibb (NYSE: BMY) unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom.

Bristol Myers Squibb Company ranks in top 10 of Pharmaceutical and Biotech Sector on the issues Americans care about most

Bristol Myers Squibb announced it has been recognized as One of America's Most JUST Companies. The ranking, presented by JUST Capital and CNBC, recognized BMS for its commitment to key social responsibilities, including employees, customers, communities, and environmental impact.

This week, BMS announced a 15-year virtual power purchase agreement (VPPA) with National Grid Renewables for 145 megawatts (MW) of solar at the Texas-based Blevins Project. Combined with the 15-year VPPA with EDP Renewables secured in 2022, this move puts BMS another step closer.

65 physicians comprise Cohort III, bringing the total to 179 participants in the program’s third year

Over 126 employees from the U.S., Canada and Puerto Rico will relay nearly 3,000 miles from the coast of Oregon to the New Jersey Shore

- Achieves $1 billion investment goal with diverse-owned suppliers

- Expanding diverse-owned supplier spend globally to increase impact

- Commitments demonstrate leadership in advancing health equity and workforce representation to better serve patients and communities

- $10 million in 2023 grant funding to 17 U.S. organizations focused on addressing social determinants of health

- Expanding aspirational workforce representation goals for those in senior leadership roles

Kareem Abdul-Jabbar is teaming up with Bristol Myers Squibb and Pfizer to raise awareness of atrial fibrillation (AFib) and its symptoms as part of the No Time to Wait campaign.

Hi, my name is Dana Walker. I’m the development program lead for genitourinary cancers here at Bristol Myers Squibb. I’m proud to lead a team of people continuing to develop treatments that help improve and extend the lives of patients dealing with genitourinary cancers.

A decade ago, the evolution of immuno-oncology transformed the landscape of therapy for patients with many cancers. Although individual immunotherapies have helped to improve outcomes for patients.

The Robert A. Winn Diversity in Clinical Trials Award Program (Winn Award Program) established by the Bristol Myers Squibb Foundation (BMSF) announced that Amgen, a global biotechnology company, has committed to contribute $8 million over the next four years.

A handful of inspirational words from author Scott Stoll served as the rallying cry for more than 350 Bristol Myers Squibb employees representing 23 nations who successfully trained and participated in four regional bicycle rides collectively known as C2C4C.

The experience was “miraculous” for Asalia, and this story is one of countless from the annual walks that support the Leukemia and Lymphoma Society (LLS), with which Bristol Myers Squibb has had a long-standing partnership.

For too many years, cancer patients in Lesotho felt life-changing cancer treatment was out of reach. No oncology clinics existed in their landlocked country ringed by steep mountains and surrounded by South Africa.

Each November marks Lung Cancer Awareness Month in the United States. Lung cancer is the leading cause of cancer deaths in the country, taking more lives than breast, colon and prostate cancers combined.

Bristol Myers Squibb has a long-standing partnership with The Leukemia & Lymphoma Society (LLS) and has been the top biopharma fundraising team for Light The Night® for more than a decade.

64 physicians comprise Cohort II, bringing the total to 116 participants in the program’s second year

Inaugural “Humankind 100” ranking celebrates companies with purpose

Alphabet scores highest in this year’s ranking

The Bristol Myers Squibb Foundation (BMSF) announced that an additional 64 physicians have been selected to receive the Robert A. Winn Diversity in Clinical Trials Career Development Award (Winn CDA).

This year, in recognition of World Psoriasis Day on October 29, we’re focusing on the mental health challenges that people living with psoriatic disease face as a result of their illness.

Meet John Loveseth, the global lead for CLIMB (Cultivating Leadership in Millennials and Beyond), one of our eight People & Business Resource Groups (PBRGs) at Bristol Myers Squibb.

We encourage all colleagues to bring their authentic selves to work, and we believe diverse thinking and a collaborative culture can help spark innovation.

Voices From R Personal Experience Inspires the Development of New Medicines Thu, 10/13/2022 - 10:30 Subheader Culture of support fosters innovation Type of Content Blog Layout Media Gallery Body As a bench scientist, Matt Labrecque has a front-row seat to the discovery of new medicines. An innate passion for science and patients powers his work, but his inspiration to help patients goes beyond the professional. Matt is a Bristol Myers Squibb employee who lives with multiple sclerosis and clinica

Scientific and Hiking Adventures To Inspire the Next Generation of Researchers Wed, 10/05/2022 - 13:30 Type of Content Article Layout Featured Media Body When Tamica D’Souza applied for a research and development internship at Bristol Myers Squibb, she had no idea that a few months later she would be loading up a 30-pound backpack in preparation for a once-in-a-lifetime opportunity to take a multi-day hiking trip through the wilderness of the Sierra Nevada Mountains in California. A culmination

From Patient to Physician: Trading Places Mon, 09/26/2022 - 11:30 Subheader By Estelle Vester-Blokland, MD, Senior Vice President, Global Medical Affairs Type of Content Blog Layout Featured Media Body At Bristol Myers Squibb, Global Patient Week stands as a pinnacle of our year-round vision to transform patients’ lives through science, bringing together our more than 32,000 employees around the world to celebrate the individuals we work each day to serve. This year, in collaboration with the pa

Keep the Wheels Turning Tue, 09/20/2022 - 12:45 Subheader By Karin Shanahan, Executive Vice President, Global Product Development and Supply Type of Content Article Layout Featured Media Body At Bristol Myers Squibb, Global Patient Week stands as a pinnacle of our year-round vision to transform patients’ lives through science, bringing together our more than 32,000 employees around the world to celebrate the individuals we work each day to serve. This year, in collaboration with the patient advo

Exploring Pathways in Immune-Mediated Diseases To Advance Patient Care Wed, 09/14/2022 - 10:30 Type of Content Article Layout Featured Media Body Alyssa Johnsen, vice president and head of clinical development, Immunology and Fibrosis, shares her perspective on the great strides that have been made in the science of modulating the body’s immune response to treat disease. Alyssa started her career as a physician-scientist, where she was focused on understanding the pathophysiology of complex auto

Using the Power of Technology To Better Serve Our Patients Mon, 09/12/2022 - 14:15 Type of Content Blog Layout Featured Media Body By Greg Meyers At Bristol Myers Squibb, Global Patient Week stands as a pinnacle of our year-round vision to transform patients’ lives through science, bringing together our more than 32,000 employees around the world to celebrate the individuals we work each day to serve. This year, in partnership with the patient advocacy groups we partner with, we asked a few of o

Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research Wed, 09/07/2022 - 12:20 Subheader More than 126 employees to ride in the company’s annual Coast 2 Coast 4 Cancer ride through towns and cities between the Oregon Coast and the New Jersey shore Type of Content Press Release Layout Featured Media Body PRINCETON, N.J., September 7, 2022 /3BL Media/ - Bristol Myers Squibb employees will embark on a cross

Schneider Electric today announced that both Amgen and Bristol Myers Squibb have joined Energize – a program designed to increase access to renewable energy for pharmaceutical suppliers.

From Numbers to Knowledge: Unlocking the Predictive Power of Data To Accelerate Transformative Science This collaborative, integrated process can lead to: followed by seven points of progress"" typeof="foaf:Image" />Tue, 08/23/2022 - 11:00 Type of Content Article Layout Featured Media Body Scientists and experts at Bristol Myers Squibb are working to revolutionize the process of drug development with sophisticated scientific strategies driven by technology. Using computer science, advanced cl

Today's Cell Therapy Insights Shaping Tomorrow Thu, 08/04/2022 - 11:00 Subheader Bristol Myers Squibb leaders share the latest in the field Type of Content Article Layout Featured Media Body While cancer remains one of the greatest global health challenges, there have been unprecedented breakthroughs and innovations in cancer research in recent years, and more people are living longer with cancer than ever before. One innovation changing the way certain cancers can be treated and offering hope t

C2C4C: Back on the Road and Bigger Than Ever Mon, 08/01/2022 - 11:00 Subheader Rides have raised more than $12 million to help fund cancer research worldwide to date Type of Content Article Layout Featured Media Body This year, C2C4C is back and bigger than ever. Nearly a decade ago, the first Coast 2 Coast 4 Cancer cycling event began with 53 employees riding 3,000 miles across the U.S. to honor loved ones impacted by cancer by raising funds for cancer research. Now in 2022, there are more than

The Future of Diversity in Clinical Trials Thu, 07/21/2022 - 11:30 Subheader Meet some of the first cohort of diverse medical students dedicated to improving health equity who have been chosen to participate in the Robert A. Winn Clinical Investigator Pathway Program. Type of Content Article Layout Featured Media Body When he was 11 years old, Cesar Ramirez contracted a joint infection that spread throughout his body. During a three-month stay in the hospital, his two physicians became not only